Last reviewed · How we verify

Serum Institute of India Pvt. Ltd. — Portfolio Competitive Intelligence Brief

Serum Institute of India Pvt. Ltd. pipeline: 1 marketed, 0 filed, 10 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 10 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
DTP-HB-Hib vaccine DTP-HB-Hib vaccine marketed vaccine Immunology
Gardasil as three dose regimen Gardasil as three dose regimen phase 3 Recombinant quadrivalent HPV vaccine Human papillomavirus (HPV) types 6, 11, 16, 18 L1 capsid protein Oncology / Infectious Disease / Immunology
Cervavac as three dose regimen Cervavac as three dose regimen phase 3 Therapeutic vaccine HPV16 and HPV18 antigens Oncology
BRV-PV Lot A + DPT-HepB-Hib + OPV BRV-PV Lot A + DPT-HepB-Hib + OPV phase 3 Combination vaccine Immunology / Infectious Disease Prevention
SII-YFV SII-YFV phase 3 vaccine Infectious Diseases
ROTARIX + DPT-HepB-Hib + OPV ROTARIX + DPT-HepB-Hib + OPV phase 3 Vaccine combination Immunology / Infectious Disease Prevention
Sii Licensed IPV Sii Licensed IPV phase 3 Infectious Diseases
Cervavac as two dose regimen Cervavac as two dose regimen phase 3 Recombinant protein subunit vaccine HPV L1 capsid protein (types 16 and 18) Oncology / Immunology
BRV-PV Lot C + DPT-HepB-Hib + OPV BRV-PV Lot C + DPT-HepB-Hib + OPV phase 3 Combination vaccine Immunology / Infectious Disease Prevention
SII Yellow Fever Vaccine SII Yellow Fever Vaccine phase 3 Live attenuated vaccine Immunology / Infectious Disease
BRV-PV Lot B + DPT-HepB-Hib + OPV BRV-PV Lot B + DPT-HepB-Hib + OPV phase 3 Combination vaccine Immunology / Infectious Disease Prevention

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Merck Sharp & Dohme LLC · 5 shared drug classes
  2. GlaxoSmithKline · 4 shared drug classes
  3. Sinovac Biotech Co., Ltd · 3 shared drug classes
  4. London School of Hygiene and Tropical Medicine · 3 shared drug classes
  5. Sanofi · 3 shared drug classes
  6. Sanofi Pasteur, a Sanofi Company · 3 shared drug classes
  7. Jiangsu Province Centers for Disease Control and Prevention · 3 shared drug classes
  8. University of Oxford · 3 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Serum Institute of India Pvt. Ltd.:

Cite this brief

Drug Landscape (2026). Serum Institute of India Pvt. Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/serum-institute-of-india-pvt-ltd. Accessed 2026-05-18.

Related